Close Menu

The Prognostic Importance of Immunohistochemical Biomarkers in Diffuse Large B-Cell Lymphoma

Issue: 
DOI: 
10.7727/wimj.2015.550
Pages: 
38-43

ABSTRACT

Objective: Molecular methods have practical difficulties in identifying sub-groups of diffuse large B-cell lymphoma (DLBCL) in routine clinical practice. The goal of this study was to subclassify DLBCL patients into sub-groups by immunohistochemical method and to evaluate the effects of sub-groups on prognosis.

Methods: For this purpose, the lymph node biopsy specimens of 40 patients with DLBCL have stained with monoclonal antibody immunostains of cluster of differentiation 10, B-cell lymphoma 6 and multiple myeloma oncogene 1 (MUM1).

Results: As a result, 6 (15%) patients have germinal centre B-cell like (GCB) phenotype and 34 (85%) patients have non-GCB phenotype. The overall survival (OS) and event-free survival (EFS) was 31.00 ± 15.49 months and 27.66 ± 17.95 months in GCB phenotype, respectively. The OS and EFS were 23.79 ± 17.82 months and 20.97 ± 17.12 months in non-GCB phenotype, respectively.

Conclusion: Multiple myeloma oncogene 1 has reached statistical significance among immunostains, and was found negatively correlated with OS and EFS. If these markers are standardized in the future, more accurate treatment schedules will be determined.

Accepted: 
16 Nov, 2015
PDF Attachment: 
e-Published: 09 Feb, 2016
Top of Page